Immune Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Immune clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 459 trials

Recruiting
Phase 2

Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

Autoimmune Lymphoproliferative Syndrome
National Institute of Allergy and Infectious Diseases (NIAID)15 enrolled3 locationsNCT06730126
Recruiting
Phase 3

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

NMDAR Autoimmune EncephalitisLGI1 Autoimmune Encephalitis
Hoffmann-La Roche152 enrolled93 locationsNCT05503264
Recruiting
Phase 3

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

Immune Thrombocytopenia
Sanofi60 enrolled20 locationsNCT07007962
Recruiting

Deciphering the Genetic Architecture of Autoimmune Diseases

Autoimmune Diseases
National Human Genome Research Institute (NHGRI)300 enrolled2 locationsNCT06948110
Recruiting
Phase 2

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

Immune Thrombocytopenia
Incyte Corporation56 enrolled40 locationsNCT07104565
Recruiting
Phase 1

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Antiphospholipid Syndrome (APS)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)+3 more
Chugai Pharmaceutical144 enrolled69 locationsNCT06371417
Recruiting
Not Applicable

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

Diabetes MellitusType 2 DiabetesType 1 Diabetes (T1D)+1 more
University of Colorado, Denver240 enrolled2 locationsNCT07011147
Recruiting

Evaluation of Patients With Immune Function Abnormalities

Chronic Granulomatous Disease (CGD)X-Linked Severe Combined Immune Deficiency (XSCID)Leukocyte Adhesion Deficiency 1 (LAD)+1 more
National Institute of Allergy and Infectious Diseases (NIAID)3,500 enrolled1 locationNCT00128973
Recruiting
Phase 2

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

Autoimmune DiseaseProteinuriaGlomerular Disease+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)30 enrolled2 locationsNCT00977977
Recruiting
Phase 3

A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Immune Thrombocytopenic Purpura (ITP)
Takeda150 enrolled98 locationsNCT06948318
Recruiting

Detection and Characterization of Host Defense Defects

Immune Defects
National Institute of Allergy and Infectious Diseases (NIAID)3,600 enrolled1 locationNCT00001355
Recruiting

Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death

Primary Immune Deficiency
National Institute of Allergy and Infectious Diseases (NIAID)5,000 enrolled7 locationsNCT00246857
Recruiting
Early Phase 1

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07507201
Recruiting
Not Applicable

Understanding of Rare Inflammatory Arthritis in Comparison to Classical Inflammatory Arthritis : Tissular Observations and Immune Infiltrate Characterization : the UTOPIC Project

Inflammatory ArthritisRare Auto-immune DiseasesImmune Checkpoint Inhibitor Related Inflamamtory Arthritis
University Hospital, Brest100 enrolled2 locationsNCT07302074
Recruiting
Phase 3

Immunomodulatory Therapy to Restore Ovarian Function and Improve Fertility in Women With Autoimmune Premature Ovarian Insufficiency

Autoimmune Prematur Ovarian Insuffience
Angelica Lindén Hirschberg40 enrolled2 locationsNCT07509840
Recruiting

Evaluation of Oxidative Stress: Comparison Between Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults

Type 1 Diabetes MellitusLatent Autoimmune Diabetes in Adult (LADA)
Fondazione IRCCS Policlinico San Matteo di Pavia75 enrolled1 locationNCT07434154
Recruiting

Natural History of Bronchiectasis

Cystic FibrosisBronchiectasisAutoimmune Disease+1 more
National Heart, Lung, and Blood Institute (NHLBI)900 enrolled1 locationNCT00943514
Recruiting

Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers

Hematopoietic and Lymphoid Cell NeoplasmMalignant NeoplasmHealthy Subject+2 more
University of Southern California625 enrolled1 locationNCT03207854
Recruiting
Phase 3

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

Autoimmune Haemolytic Anaemia
Sanofi90 enrolled91 locationsNCT07086976
Recruiting
Phase 2

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

Lymphoproliferative DisordersImmune System DiseasesPeripheral T-cell Lymphomas
National Cancer Institute (NCI)330 enrolled2 locationsNCT03922724